Medical Treatment ~ Ovarian Cancer
~ Genetics of Breast & Ovarian Cancer

Return to More Current References

Older References


    • Mitochondrial DNA mutation in serous ovarian cancer: implications for mitochondria-coded genes in chemoresistance.
    • Guerra F, Perrone AM, Kurelac I, Santini D, Ceccarelli C, Cricca M, Zamagni C, De Iaco P, Gasparre G.
    • J Clin Oncol. 2012 Dec 20;30(36):e373-8. doi: 10.1200/JCO.2012.43.5933. Epub 2012 Nov 13.
    • PARP Inhibitors: Targeting the Right Patients.
    • Azvolinsky A.
    • J Natl Cancer Inst. 2012 Dec 19;104(24):1851-2. doi: 10.1093/jnci/djs514. Epub 2012 Dec 10.
    • Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
    • Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ.
    • Cancer Res. 2012 Nov 15;72(22):5675-82. doi: 10.1158/0008-5472.CAN-12-0324. Epub 2012 Oct 11.
    • Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
    • Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, Fitzgerald LM, Krivak T, Deloia JA, Gutin A, Mills GB, Lanchbury JS.
    • Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9.
    • BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
    • Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M.
    • Epigenetics. 2012 Nov;7(11):1225-9. doi: 10.4161/epi.22561. Epub 2012 Oct 15.
    • Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    • Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.
    • Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

    Comment:

    Addicted to PAR? A closer look at PARP inhibitor sensitivity.

    Comment:

    Predicting PARP inhibitor sensitivity and resistance.

    • Olaparib , PARP1 inhibitor in ovarian cancer.
    • Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T, Bellati F, Benedetti Panici P.
    • Expert Opin Investig Drugs. 2012 Oct;21(10):1575-84. Epub 2012 Jul 13.
    • Review
    • Molecular-targeted therapies for ovarian cancer: prospects for the future.
    • Sudo T.
    • Int J Clin Oncol. 2012 Oct;17(5):424-9. doi: 10.1007/s10147-012-0461-1. Epub 2012 Aug 23.
    • Review
    • Identification of DNA Repair Pathways That Affect the Survival of Ovarian Cancer Cells Treated with a Poly(ADP-Ribose) Polymerase Inhibitor in a Novel Drug Combination.
    • Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM.
    • Mol Pharmacol. 2012 Oct;82(4):767-76. Epub 2012 Jul 25.
    • Lack of BRCA testing approval creates snag for cancer trials.
    • Azvolinsky A.
    • Nat Med. 2012 Sep 7;18(9):1310. doi: 10.1038/nm0912-1310a.
    • News
    • Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
    • Ratner ES, Sartorelli AC, Lin ZP.
    • Curr Opin Oncol. 2012 Sep;24(5):564-71. doi: 10.1097/CCO.0b013e3283564230.
    • Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
    • Stecklein SR, Jensen RA.
    • Transl Res. 2012 Sep;160(3):178-97. doi: 10.1016/j.trsl.2012.01.022. Epub 2012 Feb 9.
    • Review
    • BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
    • Stecklein SR, Kumaraswamy E, Behbod F, Wang W, Chaguturu V, Harlan-Williams LM, Jensen RA.
    • Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13650-5. doi: 10.1073/pnas.1203326109. Epub 2012 Aug 6.
    • Cancer treatment according to BRCA1 and BRCA2 mutations.
    • Maxwell KN, Domchek SM.
    • Nat Rev Clin Oncol. 2012 Aug 14;9(9):520-8. doi: 10.1038/nrclinonc.2012.123. Epub 2012 Jul 24.
    • Review
    • Olaparib in platinum-sensitive ovarian cancer.
    • Kaji D, Miura Y, Takano T.
    • N Engl J Med. 2012 Jul 12;367(2):179; author reply 179-80. doi: 10.1056/NEJMc1205423#SA1.
    • Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ.
    • Warrener P, Kim S, Williams SM, Biery M, Gordon M, Toniatti C, Cleary MA, Linsley PS, Carleton M.
    • Apoptosis. 2012 Jul;17(7):691-701. doi: 10.1007/s10495-012-0707-4.
    • HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.
    • Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K.
    • Cancer Biol Ther. 2012 Jul;13(9):766-75. doi: 10.4161/cbt.20559.
    • [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
    • Kluzek K, Białkowska A, Koczorowska A, Zdzienicka MZ.
    • Postepy Hig Med Dosw (Online). 2012 Jun 15;66:372-84.
    • BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    • Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC.
    • Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.
    • [PARP inhibitors--theoretical basis and clinical application].
    • Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.
    • Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21.
    • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
    • Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U.
    • N Engl J Med. 2012 Apr 12;366(15):1382-92. doi: 10.1056/NEJMoa1105535. Epub 2012 Mar 27.

    Comment, Letter:

    Olaparib in platinum-sensitive ovarian cancer.

    • Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
    • Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL.
    • Cancer Discov. 2012 Apr;2(4):366-75. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22.
    • A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
    • Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH.
    • Clin Cancer Res. 2012 Mar 15;18(6):1726-34. doi: 10.1158/1078-0432.CCR-11-2821. Epub 2012 Feb 3.
    • Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
    • Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J, Kaufman B.
    • J Clin Oncol. 2012 Feb 1;30(4):372-9. doi: 10.1200/JCO.2011.36.9215. Epub 2011 Dec 27.

    Comment, Editorial:

    Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.

    • Hereditary ovarian cancer: Beyond the usual suspects.
    • Pennington KP, Swisher EM.
    • Gynecol Oncol. 2012 Feb;124(2):347-53. doi: 10.1016/j.ygyno.2011.12.415.
    • Review
    • PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.
    • Zorn KK.
    • Oncology (Williston Park). 2012 Feb;26(2):128-36.

    Comment:

    The maze of PARP inhibitors in ovarian cancer.

    Comment:

    The circuitous path of PARP inhibitor development in epithelial ovarian cancer.

    • Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
    • Melichar B, Laco J, Fridrichová P, Simkovič M, Papajík T, Foretová L.
    • Acta Oncol. 2012 Jan;51(1):136-8. Epub 2011 Aug 22.
    • Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
    • Vollebergh MA, Jonkers J, Linn SC.
    • Cell Mol Life Sci. 2012 Jan;69(2):223-45. doi: 10.1007/s00018-011-0809-0. Epub 2011 Sep 16.
    • Review
    • Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals.
    • Chen SS, Michael A, Butler-Manuel SA.
    • Discov Med. 2012 Jan;13(68):7-17.
    • Biologicals in the upfront treatment of ovarian cancer: focus on bevacizumab and poly (adp-ribose) polymerase inhibitors.
    • Roux R, Zweifel M, Rustin GJ.
    • Am Soc Clin Oncol Educ Book. 2012:340-4. doi: 10.14694/EdBook_AM.2012.32.340.
    • The role of PARP inhibitors in the treatment of ovarian carcinomas.
    • Tinker AV, Gelmon K.
    • Curr Pharm Des. 2012;18(25):3770-4.
    • Review